Drug metabolism (3) Flashcards
1
Q
Polymorphism in drug metabolism
A
- Genetic variation in a biotransformation isoform which is prevalent in more than 1% of the population
- Polymorphic form is usually poorly or non-functional
- Occasionally much more efficient than wild type
- Alleles and the individual
2
Q
Polymorphism- Alleles and the individual
A
- CYP2C19 *1 = Wild type= most common
- CYP2C19 *2= Almost zero function
- CYP2C19 *3= Zero
- CYP2C19 *17= Ultra fast
3
Q
CYP2C19 alleles- white only
A
- *1 + *1= Homozygous= EM (extensive metabolism) = 73% (wild/wild type)
- *1 + *3= Heterozygous = IM (Intermediate) = 25%
- *1 + *2= Heterozygous= IM = 25%
- *2+*2= Homozygous =PM (Poor) = 2%
- *3+*3= Homozygous =PM = 2%
4
Q
CYP2C19- African only
A
- *1+*1= Homozygous = EM = 66%
- *1+*3= Heterozygous =IM = 29%
- *1+*2= Hetero =IM = 29%
- *2+*2= Homo. =PM = 4%
- *3+*3= Homo. =PM = 4%
5
Q
CYP2C19- Chinese
A
6
Q
Polymorphism key questions
A
- Real world relavence to drug use in the clinic
- Should genetic testing for polymorphisms be routine
7
Q
Key issues in polymorphism research
A
- A large number of molecular biological studies determining alleles
- A small number of actual clinical studies to determine relevance
- Established ‘Wisdom’ CYP2D6 and nortriptyline based on <200 patients and nine studies
- Tiny study numbers to predict the effects in millions ‘Vioxx’
- CYP2C19*17 = Ultra fast metabolizers alleles
- Found in 18% of Swedes and Ethiopians
- Only 4% of Chinese
8
Q
Features of polymorphism in research
A
- Many studies only record drug/metabolite levels
- Nothing about toxicity and efficacy
- Multiple pathways/Metabolites active difficulties in measuring toxicity / efficacy
- Consideration of some polymorphisms with respect to toxicity/ Efficacy
9
Q
Polymorphism and toxicity
A
- The main toxic issue in drug design Therapeutic
- E.g. Tordades des pointes (TdP)
- Long QT interval (>0.45 sec) heart cannot repolarise fast enough
- A lot of drugs can cause this but only in high concentration- such as being a PM or having an enzyme inhibitor
10
Q
CYP2D6 Polymorphism and anti-psychotic toxicity
A
- A quarter of white people have CYP2D6 *4
- 7-10% of White - *4+*4 - no functional CYP2D6
- Anti-psychotics partly cleared by CYP2D6 and Schizophrenia on old drugs twice as likely to die of TdP
- In UK ~18,000 people who are schizophrenic and *4+*4
- BUT 2009 study risk is the same for new (NON-CYP2D6) agents
11
Q
Toxicity and efficacy
TMPT and thiopurines
A
- Azathioprine/Mercaptopurine act through 6-TG metabolites
- 6-TG metabolites- efficacy and toxicity cleared by TPMT
- <10% impaired TPMT = toxicity
- <2% Ultra-rapid clearance = loss of efficacy
- Is genotype testing enough?
- NO: Effect of salicylates/GST/TPMT induction
12
Q
Irinotecan toxicity and efficacy
A
- Topoisomerase I inhibitor- used in bowel and rectal cancers
- SN-38 active metabolite cleared by UGT1A1
- >> SN-38 more toxic (lung/neutropenia/gut) and effective
- Role of UGT polymorphism?
*
13
Q
Gilbert’s syndrome and Irinotecan toxicity and efficacy
A
- UGT1A1 *28/*28 homozygous: 70% reduction in function- metabolises bilirubin
- ~7% of human population are *28+*28
- Some Gilbert’s individuals little SN-38 toxicity, others high toxicity
- Role of UGT1A7- 5 fold higher SN-38 clearance than UGUT1A1
- UGT1A7 subject to W208R and 57/TG polymorphisms
- Need to test for three polymorphisms in 2 isoforms of UGT
- Bilirubin is a strong anti-oxidants which protects cells
14
Q
Polymorphism and efficacy
A
- Many opiates cleared by CYP2D6 to active metabolites (Codeine, Oxycodone, Hydrocodone, Tramadol)
- Are these drugs useless in CYP2D6*4+*4?
- Tramadol-demethylated to M1, 200-fold more potent than parent on opiate receptors
- SLANAR et al physiolRes 56:129-136, 2007
15
Q
Polymorphisms and efficacy- opiates
A
- Even in *4/*4 M1 appears and it slowly cleared
- It does have a therapeutic effect
- M1 cleared by UGTs
- Parent has activity also
- Net effect tramadol has some analgesic effect in virtually everyone